Cooley advised Calithera Biosciences on its $80.5 million shelf-takedown offering of 7,854,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase an additional 1,024,500 shares.
Calithera, which is headquartered in South San Francisco and trades on The NASDAQ Global Select Market as “CALA,” is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
Cooley has advised with a team including Barbara Kosacz (Picture), John McKenna, Seth Gottlieb, David Ambler, Kate Nichols, Allison Peth, Natasha Leskovsek, Susan Cooper Philpot, Mark Windfeld-Hansen and Francis Wheeler.
Involved fees earner: Barbara Kosacz – Cooley LLP; John McKenna – Cooley LLP; Seth Gottlieb – Cooley LLP; David Ambler – Cooley LLP; Kate Nichols – Cooley LLP; Allison Peth – Cooley LLP; Francis Wheeler – Cooley LLP; Natasha Leskovsek – Cooley LLP; Susan Cooper Philpot – Cooley LLP; Mark Windfeld-Hansen – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Calithera BioSciences, Inc.;